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INTRODUCTION:  Gastrointestinal  stromal  tumors  (GIST)  are  the  most  frequent  mesenchymal  tumors  of
the digestive  tract.  Extraintestinal  locations  (EGIST)  have  been  described  showing  similar  pattern  of
immunohistochemical  markers  than  GIST.  Inhibitors  of tyrosine  kinases  such  as  Imatinib  or  Sunitinib
are  the  mainstay  treatment  in  the  management  of advanced  or metastatic  GIST.  Complete  pathological
response  to these  agents  is an extremely  rare  event,  especially  in  the  case  of  EGIST  due  to  its  more
aggressive  behavior  reported.
PRESENTATION  OF  CASE:  Here  we describe  the  case  of  a 61 years  old  woman,  with  an advanced  GIST,
who  was operated  after  10 months  of  Imatinib  mesylate.  The  biopsy  demonstrated  the extra  intestinal
location  of the  tumor  and a complete  pathological  response  was conﬁrmed.
DISCUSSION:  Complete  pathological  response  to Imatinib  is  a rare  event.  To  our knowledge,  this  is  the
ﬁrst  report  of complete  response  in  an  EGIST.  New  clinical,  radiological  and  metabolic  criteria  of  tumoral
response  to neoadjuvant  treatment  are  revised.
CONCLUSION:  EGIST  complete  pathological  response  to Imatinib  can be  achieved.  However,  recommen-
dation  of  systematic  neoadjuvant  therapy  with  Imatinib  remains  investigational  and  more  studies  are
warranted  in  the  future.
©  2014  The  Authors.  Published  by Elsevier  Ltd.  on behalf  of  Surgical  Associates  Ltd.  This  is  an  open
he  CCaccess  article  under  t
. Background
Gastrointestinal stromal tumors (GIST) are the most frequent
esenchymal tumors of the alimentary tract, accounting for only
.2% of all gastrointestinal tumors. Extra intestinal locations (EGIST)
ave been rarely described,1 showing similar pattern of immuno-
istochemical markers than GIST.
Inhibitors of tyrosine kinases (TKI) such as Imatinib or Suni-
inib are the mainstay treatment in the management of advanced or
etastatic GIST patients.2 Complete pathological response to these
gents is an extremely rare event,3 especially in the case of EGIST
ue to its more aggressive behavior reported.4
. Presentation of caseWe  report the case of a 61 year-old woman with no rel-
vant past medical history who was initially evaluated in a
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center without experience in oncological cases. She complained of
abdominal distension, 12 kg weight loss and early satiety eight
months before ﬁrst medical evaluation. Upper gastrointestinal
endoscopy and colonoscopy were normal. Contrast-enhanced
abdominopelvic Computed Tomography (CT) scan showed a 20 cm
highly vascular intraabdominal tumor with central necrosis and
gastric compression. Also small hepatic nodules were observed,
consistent with metastases. She was submitted to an exploratory
laparotomy showing an unresectable giant tumor, thus only an
incisional biopsy was performed and then she was derived to our
center. After oncological committee evaluation, a new CT scan was
performed (Fig. 1A and B). The parafﬁn embedded biopsy retrieved
was further studied with immunohistochemical (IHC) analyses,
which showed low expression of CD117, high CD34 and partial
DOG-1 expression, with negative Desmin and S100 expressions
(Fig. 2A and B). The morphologic and IHC analyses were compati-
ble with a GIST. Since the high risk of dissemination after the open
biopsy added to the large size of tumor and the presence of images
suspicious of liver metastases, Imatinib mesylate 400 mg  per day
was started. The treatment was  well tolerated, with no grade 3
adverse events. After 10 months of Imatinib, CT scan showed a 2 cm
decrease in tumor size and diminishment of contrast enhancement
ssociates Ltd. This is an open access article under the CC BY-NC-ND license
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Fig. 1. Intravenous contrast-enhanced abdominopelvic CT scan. (A) and (B) Sagittal and coronal slides after open laparotomic biopsy showing a 20 cm abdominal mass with
heterogeneous contrast enhancement and central necrosis. Arrow shows liver nodules suspicious of metastases; S denotes stomach. (C) and (D) Sagittal and coronal slides
after  10 months of treatment with Imatinib. Note the reduction in tumoral contrast enhancement, a minor decrease in size and stability of liver lesions.
Fig. 2. Pre and postoperative biopsies. (A) Immunohistochemistry performed in the material obtained in the initial biopsy and showed low intensity CD117-positive staining
and  in (B) a positive DOG1 expression. Picture (C) and (D) show the postoperative biopsy of the tumor resected demonstrating hyaline ﬁbrosis with intense connective tissue
without  tumoral cells. Picture (D) shows no continuity with the muscularis propia of the bowel, suggesting an EGIST.
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Fig. 3. Surgical ﬁndings after one year of Imatinib. (A) On laparotomy a large tumor was  seen with intense adherences to stomach and transverse colon. (B) A stapled distal
gastrectomy was performed with negative surgical margin.
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dFig. 1C and D). The case was discussed again in committee and
esective surgery was proposed.
On re-laparotomy the tumor was adherent to the gastric antrum
nd transverse colon, with no clear dissection plane. An en-
lock stapled distal gastrectomy and a transverse colectomy was
erformed (Fig. 3). Gastrectomy was reconstructed with a trans-
esocolic Roux-Y gastrojejunostomy and the colon was  primarily
nastomosed. The liver was explored and two small whitish nod-
les on segments IVa and V were identiﬁed and resected. No other
esions were observed in the intraoperative ultrasound. Frozen
iopsies informed calcium granulomas.
On ﬁfth postoperative day patient evolved with fever and a CT-
can showed a subhepatic abscess. She was taken to the operating
oom and a leak from the duodenal stump was conﬁrmed. Abscess
as drained and drains were placed near the duodenal stump.
hereafter she had an uneventful recovery and was discharged on
1th postoperative day with oral antibiotics.
The ﬁnal biopsy specimen showed a 20 cm × 16 cm mass
nd 2734 g weight, constituted by a highly vascularized ﬁbro-
onnective tissue with hialin ﬁbrosis and cavities with hemorrhagic
ontent. No evidence of tumor cells was seen in any sample. Also
here was no contact between the mass and the stomach or the
olon surface (Fig. 2C and D).
The oncological committee evaluated the case after surgery and
wo more years of Imatinib was proposed. At three months of
urgery, patient is asymptomatic and has not presented any adverse
vents.
. Discussion
Since the ﬁrst description of a dramatic and sustained response
f a GIST patient on 20013 it is recognized that TKI such as Imat-
nib are the mainstay treatment in the management of advanced
r metastatic GIST patients. These agents block signaling via KIT
r Platelet Derived Grow Factor Receptor Alpha (PDGFRa) by bind-
ng to the ATP-binding pocket required for phosphorylation and
ctivation of the receptor. In our case, CD117 (c-Kit) showed
ow expression, nevertheless DOG-1 (an abbreviation of Discovered
n GIST-1)5 was positive. This marker can differentiate a CD117
egative GIST from competing diagnoses in order to choose the
ppropriate treatment.
A guideline from the National Cancer Comprehensive Network
NCCN) recommends the use of Imatinib 400 mg  in advanced or
etastatic GIST in all patients. However, if molecular diagnosis is
vailable and an exon 9 KIT mutation is positive, to augment the
ose to 800 mg  is a possibility due to lesser response to standarddoses compared to exon 11 KIT mutation patients.6–8 In contrast,
the European Society of Medical Oncology suggests performing
molecular testing to all patients.9
Surgery is the only potentially cure for GIST. In borderline
resectable primary tumors, preoperative Imatinib is a possible
option but there are no randomized trials assessing the beneﬁt
of neoadjuvant treatment. Eisenberg et al.10 published a prospec-
tive study with 63 patients receiving preoperative Imatinib for
8–12 weeks. Only 7% of primary resectable GIST achieved a par-
tial response and 83% presented a stable disease.10 Whether this
poor objective response might be improved prolonging the period
of treatment is currently unknown. In another study,2 the authors
observed that the time needed to achieve a maximal response was
4–6 months, suggesting long-term treatment until one year on
these patients.3
On the other hand, the best method to assess response to neoad-
juvant treatment in GIST is still controversial. The current Response
Evaluation Criteria In Solid Tumors (RECIST) use standard images
as CT as the gold standard for measuring target lesions in solid
tumors.11 However, its use in the context of newer molecular ther-
apy is controversial.12 In some GIST responding tumors, size may
actually increase in size during early treatment as a consequence
of intratumoral hemorrhage, necrosis or myxoid degeneration.
An alternative response criteria has been proposed, including an
early decrease in tumor density on CT scan or decrease of3 10%
of size or no new lesions and no obvious progression of non-
measurable disease. The so-called Choi criteria13 outperforms the
RECIST criteria in the analysis of speciﬁc oncologic endpoints in
one report14 but not in another.15 In addition a recent report
showed that the metabolic response, measured by the change of
SUV uptake using 18F-FDG PET at baseline and days after the
start of Imatinib, might select patients with greater likelihood of
response.16
Guidelines from the NCCN recommend biopsy prior to Imat-
inib initiation.8 Probably an endoscopic ultrasound-guided ﬁne
needle biopsy was a better option in this particular case, never-
theless the oncologic principles of biopsy were not considered and
an open laparotomic biopsy was performed which theoretically
could spread tumor in the abdominal cavity, which fortunately does
not occur. The tumor showed a partial response according to Choi
criteria13 and therefore it seemed reasonable to explore the chance
of resectability, which was  completely performed.
According to the ﬁnal biopsy there are two  further points to
discuss. First, it is uncertain the origin of this tumor since histo-
logically there was  no obvious contact between the tumor and
serosal or muscular layer of the stomach or colon. Primary
Extra-Gastrointestinal Stromal Tumors (EGIST) have been
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Table  1
Comparison of studies using Imatinib as neoadjuvant therapy in gastrointestinal stromal tumor.
Study Number of patients Median time of neoadjuvant
treatment (months)
Complete surgical
resection (%)
Complete pathological response
Eisenberg10 52a (30 non-metastatic) 2 (1–3) 38.5% Not reported
Andtbacka et al.20 46 (11 non-metastatic) 12.9 (2.8–31.8) 48% (100% in
non-metastatic)
6.5% (9.0% in non-metastatic)
Bonvalot et al.21 180 (5 non-metastatic) 12 (1–30) 12% 9.0%
Raut  et al.22 69 Not reported 39.1% Not reported
Scaife  et al.18 126 10 (2–16) 13.5% 12%
Machlenkin et al.23 9b,c 1–6 66.6% 16.7%
Jakob  et al.24 16b,c 14 (6–60) 93.7% (one patient
refused surgery)
Not reported
Tielen  et al.25 22b,c 9 (2–53) 77% Not reported
Gronchi et al.26 38d 17 (7–39) 73.7% 26.3% (>90% of histological response)
Bauer  et al.27 90 (all metastatic) 12.2 (6.1–25) 12.2% 8.3%
Rutkowski et al.28 141 15 (4–32) 18.4% 8.3%
a We included only analyzable patients.
b We excluded patients who  did not receive neoadjuvant Imatinib.
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aStudy includes only patients with rectal GIST.
d We considered only operable patients.
escribed with immuno-histochemical analyses showing that
ost of them express KIT and 50% express CD34.1 Thus it is proba-
ly that Cajal’s cells are not the only origin for GISTs. EGIST seems
o behave more aggressively, more resembling of an intestinal
han a gastric GIST.4 Considering that the beneﬁt of long-term
matinib has been mainly demonstrated in high-risk patients17 it
eems reasonable to offer a total of three years of treatment to our
atient.
The other issue to discuss in this case is the complete patholog-
cal response (pCR) observed in the ﬁnal biopsy, which represents
 rare event reported. The only prospective report evaluating the
eneﬁt of neoadjuvant treatment, did not describe its pCR rate,10
ut several retrospective studies (Table 1) and case reports (not
hown in table) are able to estimate that up to 10% of patients
ill developed a pCR after the use of Imatinib. As we mentioned
bove, the use of standard response criteria such as RECIST, may
ot be useful in this setting. In one study, CT scan inaccurately pre-
icts treatment response in 30% of patients.18 In fact, in our case CT
valuation after Imatinib was consistent with stable disease failing
o anticipate the diagnosis of pCR. In other primary tumors (e.g.
reast carcinoma), the occurrence of pCR has been able to predict
ong-term outcome in several neoadjuvant studies and is there-
ore a potential surrogate marker for survival.19 However, the low
ncidence of this disease and the small experience in neoadjuvant
reatment in this group of patients, make such analysis impossi-
le to perform at this time. Whether the pCR rate may  be further
mproved by prolonging duration of treatment or not is currently
nknown. Another advantage of preoperative systemic therapy is
hat allows the evaluation dynamically and in vivo of potential
iomarkers to predict response.
. ConclusionEGIST complete pathological response to Imatinib can be
chieved. However, recommendation of systematic neoadjuvant
herapy with Imatinib remains investigational and more studies
re warranted in the future.Consent
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Key learning points
• EGIST is a rare and more aggressive tumor than traditional GIST.
• They are susceptible to treatment with inhibitors of tyrosine kinases as Imatininb.
• Complete pathological response is exceptional.
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